Table 2.

Rationale for MRgRT by disease site.

Disease Site	Enhanced Soft Tissue Visualization	Motion Management	Inter-Fraction Adaptive Re-Planning	Margin Reduction	Facilitate Dose Escalation	Relevant Studies
Prostate	✓			✓		Kishan et al. [15] Bruynzeel et al. [16] Ma et al. [17]
Pancreas	✓	✓	✓		✓	Rudra et al. [18] Parikh et al. [19]
Liver	✓	✓	✓		✓	Rosenberg et al. [20] Luterstein et al. [21] van Dams et al. [22] Ugurluer et al. [23] Henke et al. [24]
Breast	✓	✓		✓		Kennedy et al. [25] Vasmel et al. [26]
Lung		✓	✓			Henke et al. [27] Finazzi et al. [28] Regnery et al. [29] Finazzi et al. [30] Finazzi et al. [31]
Oligometastases	✓	✓	✓	✓	✓	Cuccia et al. [32] Yoon et al. [33]
Cardiac Ablation	✓	✓				Mayinger et al. [34]